Shenzhen Hepalink Pharmaceutical Group Co.,Ltd. (09989) has announced an expected annual net profit attributable to shareholders of the listed company in the range of RMB 284 million to RMB 377 million for the year ending December 31, 2025, representing a year-on-year decrease of 41.71% to 56.09%.

During the reporting period, the Group achieved significant results in expanding its global heparin preparation market business, with sales performance steadily improving across all regions and market share continuously increasing; the sales volume of enoxaparin preparations achieved double-digit growth, further consolidating the Group's global competitive position.

The year-on-year decrease in the company's net profit attributable to shareholders was primarily due to a one-time investment gain exceeding RMB 350 million (non-recurring gain or loss) recorded in the same period last year, which created a higher base for comparison.

Furthermore, during the reporting period, an associate company of the Company, due to research and development progress falling short of expectations, is expected to have a certain impact on the Group's net profit, with the specific impact subject to final confirmation by the auditing firm.

The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses for the reporting period achieved growth compared to the same period last year, mainly driven by the steady increase in main business revenue and profit.

Concurrently, the Company continued to enhance operational efficiency and promote sustained improvement in profitability by strengthening financial management and optimizing resource allocation.

Despite the expected impact from the associate company on the Group's net profit after deducting non-recurring gains and losses, the Group still achieved robust growth in this metric, demonstrating the operational resilience and continuous growth capability of its main business.